HSPB1 and breast cancer: While we focus on HSP27 inhibition as a co-treatment to cytotoxic drugs, there is evidence emerging that down-regulation of HSP27 - independent of cytotoxic compounds - induces long-term dormancy of angiogenic breast cancer cells [44].